Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins, but DRG anticipates that the number of treatment options will grow over the next ten years. Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated T1D. However, subtleties in dosage, choice of branded insulin, choice of regimen, and order in which regimens are attempted do exist between patient subpopulations and between physician types. In addition, the launch of biosimilar insulins is having a profound effect on the T1D therapy market, and we are witnessing an intricate interplay of physician and payer attitudes toward this new treatment option.
- What are the quantifiable treatment differences between adults, teenagers, and children with T1D in terms of choice of dosage, regimen, and insulin pump use?
- What is the 2017 branded patient share of insulins such as Sanofi’s Lantus and Eli Lilly’s Humalog? What is the current off-label 2017 branded patient share of SGLT inhibitors? What are the anticipated changes in prescribing patterns over the next 12 months?
- Which insulin regimen will physicians attempt first in patients with new-onset T1D? Which brands do physicians prefer to use in basal-bolus regimens? How are basal-bolus regimen ratios split in each patient subpopulation?
- What will be the market impact of Boehringer Ingelheim/Eli Lilly’s Basaglar? How resistant are physicians to payer pressure to switch patients to this less expensive product?
- What percentage of T1D patients currently use an insulin pump, and do physicians want this percentage to increase? What happens to insulin consumption patterns after patients are switched to an insulin pump? How many patients fail on an insulin pump, and how many require pump breaks each year?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that you can create specific messaging around these treatment dynamics to more effectively increase or defend your market position.
PRIMARY RESEARCH INFO
Type 1 Diabetes Current Treatment: Physician Insights is a primary market research study, evaluating physician self-reported prescribing and treatment practices for type 1 diabetes. E-mail invitations were sent to endocrinologists and PCPs to participate in an online survey. 51 endocrinologists and 51 PCPs completed the survey. The survey took approximately 30 minutes to complete. Fieldwork occurred in January 2018. To qualify, respondents met the following screening criteria:
- Board-certified in diabetes
- In practice for a minimum of 2 years and a maximum of 35 years
- Do not practice in Vermont
- More than 75% of professional time spent in clinical practice
After meeting the screening criteria, respondents were directed to an online survey, and respondents were paid an honorarium for their participation. Statistical significance testing was done when appropriate, including anticipated vs. current allocations, subgroups, and brands.
Sanofi, Novo Nordisk, Boehringer Ingelheim, Eli Lilly
Lantus, Levemir, Toujeo, Tresiba, Basaglar, Novolog, Humalog, Apidra
- Type 1 Diabetes - Current Treatment - Detailed, Expanded Analysis (US)
- Current Treatment: Physician Insights - Type 1 Diabetes - United States
Author(s): Kerri Brown, M Pharm
Kerri Brown, M.Pharm., is an analyst with Decision Resources Group, focused on finding stories in data and developing products to inform strategic decisions in the hemophilia and diabetes spaces. Kerri holds a master of pharmacy degree from King’s College London with 1st class honors. Prior to joining DRG, she was a national clinical educator at a UK diabetes start-up, and has extensive experience of diabetes medical devices. Kerri has worked at AstraZeneca, and as a pharmacist in a national psychiatric clinical trial center. In addition to her work at DRG, Kerri is a practicing pharmacist with extensive clinical experience of UK physician prescribing in diabetes.